摘要
目的 探究黄芪注射液和当归注射液辅助治疗多发性骨髓瘤的效果.方法 选取 2019 年 1 月—2022年12 月收治的多发性骨髓瘤160 例,按照随机数字表法分为4 组,每组40 例.对照组予以VTD方案化疗,黄芪组予以黄芪注射液联合VTD方案,当归组予以当归注射液联合VTD方案,联合组予以黄芪注射液、当归注射液联合VTD方案.比较4 组临床疗效、毒副反应发生率、生活质量及治疗前后血清生化指标[β2-微球蛋白(β2-MG)、游离轻链-κ(FLC-κ)、FLC-λ、白细胞介素-6(IL-6)、C反应蛋白(CRP)、碱性磷酸酶(ALP)、总Ⅰ型前胶原氨基端延长肽(TPINP)、骨钙素(BGP)]水平.结果 联合组、黄芪组、当归组总有效率及生活质量提高率均高于对照组,感染、骨髓抑制、周围神经病变及胃肠道反应发生率均低于对照组(P＜0.05).治疗 2、4 个疗程后,4 组 IL-6、CRP、β2-MG、FLC-κ、FLC-λ、TPINP均较治疗前下降,且联合组低于黄芪组、当归组、对照组,黄芪组、当归组低于对照组(P＜0.05);4 组ALP、BGP均较治疗前升高,且联合组高于黄芪组、当归组、对照组,黄芪组、当归组高于对照组(P＜0.05);但黄芪组与当归组上述血清生化指标比较差异无统计学意义(P＞0.05).结论 黄芪注射液、当归注射液联合VTD方案治疗多发性骨髓瘤,患者免疫功能及抗癌能力得以增强,毒副反应发生率明显下降,效果较为显著.
Abstract
Objective To explore the effect of Astragalus injection and Angelica injection in the adjuvant treatment of multiple myeloma.Methods A total of 160 patients with multiple myeloma treated from January 2019 to December 2022 were selected and divided into four groups according to random number table method,with 40 cases in each group.The control group was given bortezomib,thalidomide,dexamethasone(VTD)chemotherapy,the Astragalus group was given Astragalus injection combined with VTD regimen,the Angelica group was given Angelica injection combined with VTD regimen,and the combination group was given Astragalus injection and Angelica injection combined with VTD program.The clinical efficacy,incidence of toxic and side effects,quality of life and serum biochemical indexes[β2-microbulin(β2-MG),free light chain κ(FLC-κ),FLC-λ,interleukin-6(IL-6),C reactive protein(CRP),alkaline phosphatase(ALP)and total procollagen type I N-terminal propeptide(TPINP),osteocalcin(BGP)]before and after treatment were compared between the four groups.Results The total effective rate and the improvement rate of quality of life in combination group,Astragalus group and Angel-ica group were higher than those in control group,and the incidence of infection,bone marrow suppression,peripheral neu-ropathy and gastrointestinal reaction were lower than those in control group(P＜0.05).After 2 and 4 courses of treatment,IL-6,CRP,β2-MG,FLC-κ,FLC-λ and TPINP in the four groups were decreased compared with those before treatment,which were lower in the combination group than in the Astragalus group,Angelica group and control group,and lower in the Astragalus group and Angelica group than in the control group(P＜0.05).ALP and BGP in the four groups were higher than those before treatment,which were higher in the combination group than in Astragalus group,Angelica group and control group,and higher in Astragalus group and Angelica group than in the control group(P＜0.05).There was no significant difference in the above serum biochemical indexes between Astragalus group and Angelica group(P＞0.05).Conclusion Astragalus injection and Angelica injection combined with VTD regimen in the treatment of multiple myeloma can enhance the immune function and anti-cancer ability of patients,and the incidence of toxic and side effects can be significantly reduced,showing significant effects.
基金项目
河北省卫生健康委医学科学研究课题(20221891)
张家口市重点研发计划(2221177D)
维普
万方数据